Centessa Pharmaceuticals plc
23.98-1.02 (-4.08%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · CNTA · USD
Key Stats
Market Cap
3.22BP/E (TTM)
-Basic EPS (TTM)
-1.85Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Centessa Pharmaceuticals posted a Q2 net loss of $50.3M, up 15% y/y from $43.8M, driven by a 30% jump in R&D expenses to $42.7M as the OX2R agonist program ramped up with ORX750's Phase 2a launch and ORX142's Phase 1 start, while G&A held steady at $11.9M. YTD through June 30, 2025, revenue hit $15M from the February Genmab LockBody license upfront, offsetting a 76% YTD net loss rise to $76.5M versus $81.9M last year, with diluted EPS improving to $(0.57) from $(0.78) on 133M shares. Cash and investments fell to $404M from $482M at year-end, funding operations into mid-2027, while $110M debt under the Oxford LSA matures in 2029 at 8.28-10.50% interest. The Genmab deal closed in February 2025 for $15M upfront, unlocking up to $234M milestones per product and mid-single-digit royalties. Yet single-program reliance amplifies risks from clinical setbacks.
8-K
Centessa Q2 loss widens on R&D push
Centessa Pharmaceuticals reported Q2 2025 net loss of $50.3 million, up from $43.8 million last year, driven by $42.7 million in R&D expenses amid advancing its orexin receptor 2 agonist pipeline. ORX750's Phase 2a CRYSTAL-1 study progresses for narcolepsy and hypersomnia, with data expected this year; ORX142's Phase 1 trial just started, targeting neurological disorders. Cash stands at $404.1 million, funding into mid-2027. Pipeline momentum builds, yet clinical risks loom.
8-K
AGM resolutions approved
Centessa Pharmaceuticals held its 2025 Annual General Meeting on June 20, with 124,956,837 ordinary shares represented, establishing a quorum. Shareholders re-elected directors Arjun Goyal and Samarth Kulkarni, ratified KPMG LLP as auditors for the year ending December 31, 2025, and approved the remuneration report and policy alongside share allotment authorities up to £133,184 nominal value. All resolutions passed, signaling strong governance alignment. No dividends recommended for 2024.
8-K
FDA clears ORX142 Phase 1 trial
Centessa Pharmaceuticals secured FDA clearance for its IND on June 16, 2025, greenlighting a Phase 1 trial of ORX142, a selective OX2R agonist targeting neurological and neurodegenerative disorders. The study assesses safety, tolerability, pharmacokinetics in healthy volunteers, plus pharmacodynamics in sleep-deprived subjects using MWT and KSS tests. Dosing starts soon. Data readout slated for this year. Yet recruitment risks loom large.
8-K
New CAO appointment
Centessa Pharmaceuticals appointed Raphael Deferiere as Chief Accounting Officer on May 27, 2025, designating him principal accounting officer while John Crowley remains CFO. Deferiere, a 46-year-old CPA with eight years as an Assurance Partner at Ernst & Young, brings deep audit expertise. His package includes $400,000 base salary, 35% target bonus, and options for 165,000 ADSs vesting over four years. This bolsters financial oversight amid biotech demands.
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
CNSP
CNS Pharmaceuticals, Inc.
7.60-0.71
CNTX
Context Therapeutics Inc.
1.15-0.02
CTNM
Contineum Therapeutics, Inc.
10.90-0.13
EPIX
ESSA Pharma Inc.
0.20+0.00
NRXP
NRX Pharmaceuticals, Inc.
3.05+0.05
NVCT
Nuvectis Pharma, Inc.
6.77+0.34
ORKA
Oruka Therapeutics, Inc.
27.61+0.17
OTLC
Oncotelic Therapeutics, Inc.
0.10+0.00
TSHA
Taysha Gene Therapies, Inc.
5.01+0.02